US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Invion Ltd (IVX) 銘柄情報

Invion Ltd (IVX)

0.048

0.002

(4.35%)

終了 6月6日 3:00PM

Invion Ltd (IVX) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.048

( 4.35% )

買値

0.046

売値

0.05

出来高

383,147

0.046 日の範囲 0.048

0.044 52 週間の範囲 0.20

時価総額

前日終値

0.046

始値

0.046

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 173,765

発行済株式数

96,965,315

配当利回り

PER

-0.34

1 株当たり利益 (EPS)

-0.13

歳入

-

純利益

-10.5M

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-ge... Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. 詳細を表示

セクター

Healthcare

業界

Pharmaceuticals

ウェブサイト

www.inviongroup.com

本社

Melbourne, Australia

設立

2026

Invion Ltd is listed in the Healthcare sector of the オーストラリア証券取引所 with ticker IVX. The last closing price for Invion was AUD0.05. Over the last year, Invion shares have traded in a share price range of AUD 0.044 to AUD 0.20.

Invion currently has 96,965,315 shares in issue. The market capitalisation of Invion is AUD4.65 million. Invion has a price to earnings ratio (PE ratio) of -0.34.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.002	-4	0.05	0.05	0.044	99320	0.04588056	DE
4	-0.01	-17.2413793103	0.058	0.072	0.044	328416	0.05265389	DE
12	-0.029	-37.6623376623	0.077	0.08	0.044	189110	0.05737631	DE
26	-0.051	-51.5151515152	0.099	0.11	0.044	152299	0.06937276	DE
52	-0.067	-58.2608695652	0.115	0.2	0.044	131044	0.08871594	DE
156	0.042	700	0.006	0.43	0.002	1085098	0.01038262	DE
260	0.031	182.352941176	0.017	0.43	0.002	2757286	0.01803731	DE

IVX - Frequently Asked Questions (FAQ)

What is the current Invion Ltd share price?

The current share price of Invion Ltd is AUD 0.048

How many Invion Ltd shares are in issue?

Invion Ltd has 96,965,315 shares in issue

What is the market cap of Invion Ltd?

The market capitalisation of Invion Ltd is AUD 4.65M

What is the 1 year trading range for Invion Ltd share price?

Invion Ltd has traded in the range of AUD 0.044 to AUD 0.20 during the past year

What is the PE ratio of Invion Ltd?

The price to earnings ratio of Invion Ltd is -0.34

What is the registered address of Invion Ltd?

The registered address for Invion Ltd is 385 Bourke Street, Melbourne, Victoria, 3000

What is the Invion Ltd website address?

The website address for Invion Ltd is www.inviongroup.com

Which industry sector does Invion Ltd operate in?

Invion Ltd operates in the Pharmaceuticals sector

US Market News

US Market News 6分前

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA BerobenatideJune 6, 2026 9:00 AM
Business Wire Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in

Investor082

Investor082 6分前

They are all a bunch of BS artists! They have trapped many naive retail families over the years by providing false hope and expectations.

Investor082

Investor082 8分前

See you in 2028 then! LP is likely to abandon Eden before that at some point than secure a commercial certification in 2028.

Keep a ton of dry powder. Looking forward to you bragging about averaging down in the coming weeks and months, LOL! ;)

Investor082

Investor082 11分前

In that case, forget about 2026 and 2027. Likely 2028 as well. C lab and Eden won’t certified for commercial production until 2028 at the earliest. Its more likely they will abandon Eden than secure commercial certification even in 2028. Have fun with the endless dilution in pennies! ;)

WhiteOwl

WhiteOwl 12分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

hardlesson

hardlesson 15分前

You're one of the hardest working guys on ihub. Banging out the charts on a Saturday morning. Thanks always, and have a good weekend. :)

Investor082

Investor082 15分前

LP will be back there again in a couple years still pleading for a change (pathway act) so she can submit regulatory application to FDA in 2030, LOL!

Meanwhile outstanding shares ballooned to 5B+, LOL! ;)

WhiteOwl

WhiteOwl 15分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

glenn1919

glenn1919 19分前

BCDA......BMGL.......BGMS......ACCL......CMND.........CGTL...........https://stockcharts.com/sc3/ui/?s=CMND&p=w&yr=1&mn=3&dy=0&id=p96837884856

Investor082

Investor082 19分前

No excuses when LP disappoints on this, OK?

I will check in on this message whenever there is a decision, LOL! ;)

WhenLambo

WhenLambo 20分前

FIFA is already on public record marketing them, what could be bigger than that? They’ll continue to put VuMe out there next week

train21

train21 21分前

DRIVEN IS BACK
so I guess we going to see 5 cents again ? well are we ?

Investor082

Investor082 22分前

Don't let LP and her toxic financiers screw you year after year, LOL! ;)

Instead invest in well known AI and tech stocks run by solid management crew.

glenn1919

glenn1919 23分前

STAK......SPHL.....SMTK......SAOR.....SNBR.......SCAG.....SPPL..................................https://stockcharts.com/sc3/ui/?s=SCAG&p=w&yr=1&mn=3&dy=0&id=p96837884856

jackinthegreen

jackinthegreen 24分前

Exactly - another round of press and hype can drive the price up a bit, but without substantial new contracts and revenue outside the consumer electronics space, it will only be a temporary bump. We’ve been here before - buying on the rumor is great, but what we need is actual profitability.

train21

train21 24分前

BOTH CEOs BLOCKED ME ON X
I MUST HAVE HIT THE NAIL ON THE HEAD
ANY CEO THAT BLOCKS QUESTIONS OF THEIR DECISIONS IS HIDING SOMETHING BIG AND BAD ???

rodman

rodman 24分前

There appears to be some life left in UEEC based upon the buying and pps increase this week.

cottonmather

cottonmather 25分前

Drey Dossier. The WH Ballroom ain't what it used to be. 17 minutes https://youtu.be/VbJ4ilDvGyc?si=DispyZYqLVQNJyms

USAFpatriot

USAFpatriot 25分前

Annual meeting 8k.

https://investorshub.advfn.com/stock-market/NASDAQ/novocure-NVCR/stock-news/98686681/form-8-k-current-report

train21

train21 26分前

$GTVH YOU ALL NEED TO FILE COMPLAINTS ON THE $OTC WEB SITE AND THE $FINRA WEB SITE
I CAN NOT JUST BE THE ONLY ONE FILING COMPLAINTS HERE ? SOME OF YOU GUYS LOST THOUSANDS $$$$$
CASEY IS A SHARE SELLING SCAMMMER AND MEDIA POSTING LIAR ......... AND THATS ALL THIS STOCK IS

HGiLS

Absolutely — let’s build the full, structured deep-dive you asked for. Below is everything:

• All Eliquis ANDA filers
• Their litigation outcomes
• Each filer’s non-infringement arguments
• Why none succeeded
• Drugs where generics did win using alternative

peafunke

peafunke 28分前

You told ‘who’ so? The fifa concerts are this coming week.

HGiLS

Yes — Eliquis (apixaban) has exactly the kind of ANDA litigation you’re asking about: cases where a generic filer challenged the Orange Book patents and argued non-infringement because their own formulation or manufacturing approach did not fall within the scope of the listed patents.

Teddytropics

Teddytropics 31分前

I will leave it up to you to decide..

I ask myself.. why is this guy so obsessed with Jason Black..?

That he wants to 'to tell on Jason Black' to all..

Where Jason Black isn't involved here anymore except for the CNNA OTC page still listing him..

Xtrackers II TIPS US Inf...

Dynamic Active Mining Op...

STMicroelectronics NV AD...

BMO Global Communication...

Nuveen ESG Dividend

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。